Company MYOS Corp Nasdaq

MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.